摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(1,3-dimethyl-2,6-dioxo-2,3-dihydro-1H-purin-7(6H)-yl)-N-(4-(methylthio)-3-(trifluoromethyl)phenyl)acetamide | 1257240-86-0

中文名称
——
中文别名
——
英文名称
2-(1,3-dimethyl-2,6-dioxo-2,3-dihydro-1H-purin-7(6H)-yl)-N-(4-(methylthio)-3-(trifluoromethyl)phenyl)acetamide
英文别名
2-(1,3-dimethyl-2,6-dioxopurin-7-yl)-N-[4-methylsulfanyl-3-(trifluoromethyl)phenyl]acetamide
2-(1,3-dimethyl-2,6-dioxo-2,3-dihydro-1H-purin-7(6H)-yl)-N-(4-(methylthio)-3-(trifluoromethyl)phenyl)acetamide化学式
CAS
1257240-86-0
化学式
C17H16F3N5O3S
mdl
——
分子量
427.407
InChiKey
JRTJKKJAQRTKMU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    29
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    113
  • 氢给体数:
    1
  • 氢受体数:
    8

文献信息

  • [EN] COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO TRPA1<br/>[FR] COMPOSÉS UTILES DANS LE TRAITEMENT DE TROUBLES ASSOCIÉS À TRPA1
    申请人:HYDRA BIOSCIENCES INC
    公开号:WO2010138879A1
    公开(公告)日:2010-12-02
    Compounds and compositions for treating disorders related to TRPAl are described herein.
    这里描述了用于治疗与TRPAl相关疾病的化合物和组合物。
  • Use of TRPA1 Antagonists to Prevent or Treat Infections Caused by Biological-Warfare Agents
    申请人:Moran Magdalene M.
    公开号:US20130310345A1
    公开(公告)日:2013-11-21
    Provided are methods for preventing and treating injuries caused by exposure to biological warfare agents. The methods include administering to a subject in need thereof an effective amount of a TRPA1 antagonist or a pharmaceutically acceptable salt thereof. In an embodiment the TRPA1 antagonist is selected from the group consisting of compounds of formula I and compounds of formula II as described herein.
  • USE OF TRPA1 ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BIOLOGICAL-WARFARE AGENTS
    申请人:HYDRA BIOSCIENCES, INC.
    公开号:US20170151248A1
    公开(公告)日:2017-06-01
    Provided are methods for preventing and treating injuries caused by exposure to biological warfare agents. The methods include administering to a subject in need thereof an effective amount of a TRPA1 antagonist or a pharmaceutically acceptable salt thereof. In an embodiment the TRPA1 antagonist is selected from the group consisting of compounds of formula I and compounds of formula II as described herein.
  • US9260430B2
    申请人:——
    公开号:US9260430B2
    公开(公告)日:2016-02-16
查看更多